EPISODE · May 27, 2026 · 4 MIN
MHRA-NICE Pathway Under Fire, Clinical Trial Targets Hit
Episode 13 — 27 May 2026 LSE expert challenges the new UK aligned drug approval pathway as industry-favoring while EU reports progress on 2030 clinical trial targets. NICE approves first HER2-targeted therapy for bile duct cancer as regulatory reforms reshape the clinical research landscape. Hosted by Marcus and Sara. Access Brief — Daily briefings on HEOR, HTA strategy and the evidence access landscape. Full transcript and sources at outcomes-analytica.no/podcast
Embed this episode
Ready to play
MHRA-NICE Pathway Under Fire, Clinical Trial Targets Hit
No transcript for this episode yet
Similar Episodes
No similar episodes found.